Catalog No.: PC-24479Not For Human Use, Lab Use Only.
RJG-2051 is a potent, selective and covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with IC50 of 13 nM, shows clear selectivity against AKR1C1 (2350-fold), AKR1C2 (1790-fold), and AKR1C4 (429-fold).
RJG-2051 is a potent, selective and covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with IC50 of 13 nM, shows clear selectivity against AKR1C1 (2350-fold), AKR1C2 (1790-fold), and AKR1C4 (429-fold).
RJG-2051 exhibits proteome-wide selectivity, shows negligible cross-reactivity with AKRs or other proteins across 1800+ tyrosine and lysine sites quantified by chemical proteomics.
RJG-2051 engages a noncatalytic tyrosine site (Y24).
RJG-2051 has IC50 of 27 nM in Coumberone reduction assays.
